FindAir, the Polish medtech innovator revolutionizing asthma and COPD management with intelligent inhaler technology, today announced the successful closing of a PLN 7 million seed funding round. The investment was led by 4growth VC alongside co-investment from the NCBR Investment Fund (NIF). Proceeds will fuel continued R&D and support the company’s rapid commercial expansion in the United States.
Founded in 2017 by Michał Czyż, Tomasz Mikosz and Jacek Mikosz, FindAir develops smart sensor attachments and an end-to-end software platform that capture real-time medication usage data, enable remote patient monitoring and facilitate physician communication. Recognized as one of Europe’s pioneers in smart inhaler solutions—and among the top three global players—FindAir’s product suite already covers the majority of prescription inhaler types used to treat asthma and chronic obstructive pulmonary disease (COPD).
“We collaborate with leading European clinical and research centers that specialize in asthma and COPD,” said Tomasz Mikosz, CEO of FindAir. “As the only European company offering such a comprehensive range of smart inhaler attachments, we’re committed to extending our portfolio to include all of the most widely used inhaler devices. This new funding will accelerate our product development efforts.”
FindAir’s devices are certified as medical devices across the European Union and are currently deployed in hospitals throughout the Netherlands, Belgium, France, Greece, Ireland and Germany. They are also available in the United Kingdom and United States, where U.S. sales already account for 40 percent of the company’s revenue.
“We’re seeing explosive growth in U.S. telehealth platforms, yet a shortage of patient medication-adherence monitors,” added Mikosz. “This funding allows us to rapidly meet that demand by scaling our operations stateside. Major pharmaceutical companies are increasingly partnering with us as their external R&D lab for smart inhaler and related technologies.”
According to the World Health Organization, more than 300 million people worldwide live with asthma, and another 250 million suffer from COPD. Both conditions rank among the leading causes of chronic morbidity and mortality—and their impact is expected to rise.
4growth VC, known for backing internationally active medtech companies such as Saventic Health and Talkie.ai, led the round.
“FindAir offers a proven, market-ready product line—hardware, software and deep domain expertise honed over seven years,” said Krzysztof Bachta, Managing Partner at 4growth VC. “With a target patient base in the hundreds of millions and the global shift toward remote care, the company is poised for dynamic growth in the smart-inhaler space.”
NIF, which focuses on investments in small and medium-sized enterprises, also joined the round.
“We look for strong teams with clear strategies and the potential to solve meaningful problems,” said Paweł Materniak, Investment Director at NCBR Investment Fund. “FindAir’s innovative solution and outstanding team convinced us to support their next phase of growth.”
About FindAir
FindAir is a Warsaw-based medical technology company founded in 2017. Its integrated system—comprising smart inhaler attachments, a mobile app and a web-based data platform—enables healthcare providers to remotely monitor inhaler use and engage patients in real time. Since launching its first product in 2019, FindAir has expanded its offering to include smart sensor kits compatible with leading inhaler brands such as Ventolin®, Seretide®, Serevent®, Flixotide® and Budiair®.
About 4growth VC
4growth VC is a European venture capital fund investing in early-stage startups with global ambitions in the digital health and medtech sectors. The fund supports companies that leverage technology to improve patient outcomes and healthcare efficiency.
About NCBR Investment Fund (NIF)
The NCBR Investment Fund is a public-private fund specializing in growth-stage investments in small and medium-sized Polish enterprises. NIF focuses on innovative technologies with high market potential.
